Regulatory sequences capable of conferring expression of a heterologous DNA sequence in endothelial cells in vivo and uses thereof

US7011973B1 · kind B1 · utility

Assignee

• Max-Planck-Gesellschaft zur Föderung der Wissenschaften e.V. · US

Inventors

• Werner Risau · Gräfelfing, DE
• Volker Rönicke · Frankenthal (Pfalz), DE
• Georg Breier · Bad Nauheim, DE

Key dates

• Filing date: Jun 3, 1998
• Grant date: Mar 14, 2006
• Expiry date: Jun 3, 2018

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2830/85
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Described are recombinant DNA molecules comprising the regulatory sequences of an intron of the Endothelial Growth Factor (VFGF) receptor-2 gene (Flk-1) or of a gene homologous to the Flk-1 gene, being capable of conferring expression of a heterologous DNA sequence in endothelial cells, preferably in vivo. Vectors comprising said DNA molecules as well as host cells containing the same are provided. Also provided are pharmaceutical and diagnostic compositions comprising such recombinant DNA molecules and vectors. Furthermore, cells and transgenic non-human animals, comprising the aforementioned recombinant DNA molecules or vectors stably integrated into their genome and their use for the identification of substances capable of suppressing or activating transcription of a gene in endothelial cells are described. Described is further the use of the before described recombinant DNA molecules and vectors for the preparation of pharmaceutical compositions for treating, preventing, and/or delaying a vascular or tumorous disease in a subject. Furthermore, uses of the recombinant DNA molecules and vectors of the invention for the preparation of pharmaceutical compositions for inducing a vas…